Table 2.
Rheumatoid arthritis and osteoarthritis variables.
| Rheumatoid arthritis | ||
|---|---|---|
| Variable | Median (IQR) | |
| Age at onset | 41.5 (19) | |
| Age at diagnosis | 42.5 (20) | |
| Number of painful joints | 2 (6) | |
| Number of swollen joints | 2 (2) | |
| DAS-28 (ESR) | 3.445 (1.2) | |
| DAS-28 (CRP) | 2.610 (1.3) | |
| Variable | n (%) | |
| Extra-articular manifestations | 8 (15.4) | |
| Erosivity | 30 (57.7) | |
| RF-positive | 44 (84.6) | |
| ACPA-positive | 45 (86.5) | |
| Antinuclear antibodies-positive | 42 (80.8) | |
| Polyautoimmunity | 6 (11.5) | |
| Current treatment | Methotrexate | 34 (65.4) |
| Other csDMARDsa | 30 (57.7) | |
| Antimalarialsb | 3 (5.8) | |
| GCs | 39 (75) | |
| bDMARDsc | 17 (32.7) | |
| Tofacitinib | 2 (3.8) | |
| NSAIDs | 5 (9.6) | |
| Previous treatment | csDMARDs | 22 (42.3) |
| bDMARDs | 7 (13.5) | |
| Osteoarthritis | ||
| Variable | n (%) | |
| Patients with Fibromyalgia | 20 (37) | |
| Patients with Tendinopathy/Bursitis | 13 (24.1) | |
| Inflammatory component of Osteoarthritis | 6 (11.1) | |
| Physical and Rehabilitation follow-up treatment | 22 (40.7) | |
| Physiotherapy | 22 (40.7) | |
| Current treatment | Under pharmacology therapy | 51 (94.4) |
| NSAIDs | 2 (3.7) | |
| Analgesics, Opioids | 30 (55.6) | |
a
Leflunomide, sulfasalazine;
b
Chloroquine, Hydroxychloroquine;
c
abatacept, rituximab, tocilizumab; ACPA, anti-citrullinated peptide antibodies; bDMARDS, biological disease-modifying antirheumatic drugs; CRP, C-reactive protein; csDMARDS, conventional synthetic disease-modifying antirheumatic drugs; ESR, Erythrocyte; GCs, Glucocorticoids; NSAIDs, non-steroidal anti-inflammatory drugs.